Franklin Resources Inc. Has $1.60 Million Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Franklin Resources Inc. boosted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 1,714.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 273,706 shares of the company's stock after purchasing an additional 258,625 shares during the period. Franklin Resources Inc. owned approximately 0.48% of Olema Pharmaceuticals worth $1,596,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of OLMA. KLP Kapitalforvaltning AS acquired a new position in shares of Olema Pharmaceuticals in the 4th quarter worth $30,000. Teacher Retirement System of Texas acquired a new position in shares of Olema Pharmaceuticals in the fourth quarter worth about $60,000. Vontobel Holding Ltd. purchased a new position in shares of Olema Pharmaceuticals in the fourth quarter worth approximately $62,000. Fox Run Management L.L.C. acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter valued at approximately $80,000. Finally, SG Americas Securities LLC lifted its position in shares of Olema Pharmaceuticals by 33.8% in the 4th quarter. SG Americas Securities LLC now owns 17,475 shares of the company's stock valued at $102,000 after acquiring an additional 4,419 shares in the last quarter. Institutional investors own 91.78% of the company's stock.

Wall Street Analyst Weigh In

OLMA has been the topic of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th. Oppenheimer reissued an "outperform" rating and issued a $25.00 price target (down from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a research report on Friday, March 28th.

Olema Pharmaceuticals Trading Up 3.8 %

OLMA stock traded up $0.16 during mid-day trading on Friday, hitting $4.42. The stock had a trading volume of 615,557 shares, compared to its average volume of 859,270. The stock has a market capitalization of $302.03 million, a price-to-earnings ratio of -2.02 and a beta of 2.10. The company has a fifty day moving average of $4.20 and a 200 day moving average of $7.07. Olema Pharmaceuticals, Inc. has a 1-year low of $2.86 and a 1-year high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12. As a group, sell-side analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.